



## Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

February 20, 2025

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025.

### Conference Call/Webcast Information:

**Date:** Thursday, February 27, 2025

**Time:** 4:30 pm Eastern Time (1:30 pm Pacific Time)

**Webcast:** [Pre-register here](#)

**Dial-In:** (800) 715-9871 toll-free or (646) 307-1963 for international callers

**Conference ID:** 8120798

A live webcast of the company presentation will be available on the "[Investors](#)" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

### About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit [www.xenon-pharma.com](http://www.xenon-pharma.com).

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

### Contacts:

*For Investors:*

Chad Fugere  
Vice President, Investor Relations  
(857) 675-7275  
[investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)

*For Media:*

Colleen Alabiso  
Senior Vice President, Corporate Affairs  
(617) 671-9238  
[media@xenon-pharma.com](mailto:media@xenon-pharma.com)



Source: Xenon Pharmaceuticals Inc.